ITBMed is a Stockholm, Sweden–based biopharmaceutical company focused on developing specific immunomodulatory biologics for use primarily in organ and stem cell transplantation. Its lead candidate, Siplizumab, is a monoclonal antibody in late-stage clinical development. The company intends to use the funds to develop Siplizumab in its lead indication of induction of tolerance in organ transplantation, where it has been used in a phase II trial to permit organ transplants without the need for lifelong immunosuppression. ITBMed also maintains a preclinical R&D profile and a collaboration with Columbia University to generate novel IP for new indications and treatments. Leadership includes CEO Dr. Erik Berglund; the research that led to Siplizumab was initiated by Prof. David H. Sachs, who serves as CTO.

Total raised

$67M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2018